About Antares Therapeutics
Antares Therapeutics is a Boston-based biotechnology company developing transformational, first-in-class precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with large unmet need. Founded in 2025 as a spin-out from Scorpion Therapeutics, it leverages an integrated drug discovery platform combining medicinal chemistry, target biology, and predictive sciences to advance a robust preclinical pipeline primarily in precision oncology.
Company details
Funding
Total raised
$177M
Last stage
Series A
Investors
Founders
Adam Friedman
M.D., Ph.D. Former CEO of Scorpion Therapeutics. Previously Founder, President and CEO of Vivid Biosciences. Attended Harvard Medical School.
LinkedInKeith Flaherty
M.D. Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School. Co-founded Loxo Oncology and several other oncology companies.
Liron Bar-Peled
Named as a co-founder of Scorpion Therapeutics, the predecessor entity to Antares Therapeutics.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.